在压力过载引起的心脏缩和心脏功能障碍期间,SH2B1对葡萄糖代谢的影响
Beilei Liu1,2,3, Xuguang Liu1,2,3, Shan Hu4
1Department of Cardiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
Clinical and experimental pharmacology & physiology
|July 4, 2023
概括
通过降低葡萄糖代谢,SH2B1 Knockdown可以缓解心脏缩和功能障碍. 这通过PI3K/AKT通路发生,在压力过载时影响心脏功能.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 代谢研究研究 代谢研究
背景情况:
- 压力过载会导致心脏缩和功能障碍.
- 改变心脏新陈代谢是心脏病的标志.
- 在压力下,SH2B1在心脏代谢中的作用尚不清楚.
研究的目的:
- 研究SH2B1在心脏葡萄糖代谢中的作用.
- 阐明SH2B1在压力过载引起的心脏缩和功能障碍中的机制.
主要方法:
- 构建了一个压力过大的心脏缩模型.
- 使用SH2B1-siRNA来淘汰SH2B1的表达.
- 评估心脏形态,过度缩标志物,葡萄糖代谢 (GLUT1,GLUT4,IR,糖分解,吸收),脂肪酸代谢和心脏功能 (心声图).
- 使用激活器探索PI3K/AKT通路.
主要成果:
- 压力过载增加了心脏缩,功能障碍,葡萄糖代谢和糖解,同时降低了脂肪酸代谢.
- SH2B1的敲击缓解了缩和功能障碍,降低了葡萄糖代谢和糖解,并增强了脂肪酸代谢.
- 激活PI3K/AKT可以逆转SH2B1对心脏新陈代谢的影响.
结论:
- 通过降低心脏葡萄糖代谢,SH2B1敲击减轻心脏缩和功能障碍.
- 在压力过载引起的心脏缩和功能障碍期间,SH2B1通过PI3K/AKT通路调节心脏葡萄糖代谢.
相关概念视频
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Hypertension II: Pathophysiology
20
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
20
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467


